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Giancarlo Agnelli and colleagues have recently revealed results of the 
CARAVAGGIO study at the American College of Cardiology and World Congress of 
Cardiology’s virtual scientific sessions. The outcomes of this trial, simultaneously published 
in the The New England Journal of Medicine [1], support the inclusion of apixaban as another 
direct oral anticoagulant (DOAC) for cancer patients with newly diagnosed incidental or 
symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE). This study 
seems to finish the ongoing discussion on the possibility of using DOACs in cancer-
associated thrombosis (CAT) and change the paradigm, setting the low-molecular-weight 
heparin (LMWH) as a drug of choice and gold standard in this indication.  
Venous thromboembolism (VTE) is the second-leading cause of mortality in cancer 
patients receiving chemotherapy [2]. The adjusted occurrence of VTE is a significant 
predictor of limited survival within the first year for all cancer types (HR 1.6–4.2; p < 0.01) 
[3]. Moreover, the risk of VTE varies depending on the type of cancer, the stage of metastatic 
disease, and receipt of some anti-cancer therapy [4]. The highest risk refers to pancreatic 
cancer, hematological malignancies, lung, gastric, and brain cancer. The CLOT trial, 
published in 2003, showed superior efficacy of dalteparin compared to vitamin K antagonist 
in the prevention of recurrence of cancer-associated VTE and similar bleeding rate in both 
groups [5]. It was the basis for explicit recommendations for initial and long-term CAT 
treatment with LMWH in the following years. Recently the European Society of Cardiology 
Guidelines suggested that “edoxaban or rivaroxaban should be considered as an alternative 
LMWH, with a word of caution for patients with gastrointestinal cancer due to the increased 
bleeding risk with DOACs” [6]. The latter was added to underline that the increased risk of 
bleeding may counterbalance the benefits of anticoagulation therapy in cancer patients. The 
risk of bleeding in patients treated with DOACs is an essential problem in “mucosal” types of 
cancer occurring in the gastrointestinal tract and urinary system. Last but not least is the 
possibility of unfavorable interactions of DOACs with chemotherapy, which may occur 
during concomitant use. 
In the Hokusai VTE Cancer study, oral edoxaban was confirmed to be noninferior to 
subcutaneous dalteparin concerning the composite outcome of recurrent VTE or major 
bleeding, but the rate of major bleeding was higher with edoxaban than with dalteparin [7]. 
Similarly, SELECT-D trial rivaroxaban has shown low VTE recurrence and but the results for 
major bleeding was 4% for dalteparin and 6% for rivaroxaban. Unfortunately, the adequate 
rates for clinically relevant non-major bleeding were 4% for dalteparin and 13% for 
rivaroxaban [8]. Of note, both studies did not exclude patients with cerebral metastases and 
brain tumors. 
The newly published CARAVAGGIO study is a multinational, randomized, open-
label, investigator-initiated study to compare efficacy and safety of apixaban and dalteparin in 
1170 cancer patients with VTE [1]. Patients with basal-cell or squamous-cell carcinoma of the 
skin, primary brain tumor, brain metastases, and acute leukemia were excluded, but all other 
types neoplastic disease may have been included in the study. Approximately one-third of 
patients presented cancer at gastrointestinal sites. 585 patients were assigned to receive 
apixaban at a dose of 10 mg twice daily for the first week and 5 mg twice daily subsequently 
and 585 patients were assigned to receive dalteparin at a dose of 200 IU/kg of body weight 
subcutaneously once daily for the first month and 150 IU/kg of bodyweight subsequently over 
a period of 5 months.  The primary efficacy end-point was defined as the recurrence of VTE. 
The principal safety outcome was defined as major bleeding. Finally, 1155 patients were 
included in further analysis. Patients with PE accounted for 52.8% and 57.7% in the apixaban 
and dalteparin groups, respectively. Approximately 20% of the cases were individuals with 
incidental DVT or PE who were diagnosed during diagnostic procedures performed for 
reasons other than clinical suspicion of VTE. Ninety-seven percent of cases presented active 
cancer at enrollment.  
The primary efficacy end-point occurred in 5.6% patients in the apixaban group (32 
patients: 13 recurrent DVTs, 19 recurrent PE, including 4 cases of fatal PE) compared to 7.9% 
(46 patients: 15 recurrent DVT, 32 recurrent PE, including 3 cases of fatal PE) in the 
dalteparin group (p < 0.001 for noninferiority; p = 0.09 for superiority in favor of apixaban). 
Major bleeding occurred in 3.8% (22) of patients in the apixaban group and 4% (23) of 
patients in the dalteparin group. Moreover, major gastrointestinal bleeding occurred in 1.9% 
(11) of patients in the apixaban group and 1.7% (10) patients in the dalteparin group. There 
were two fatal bleeding episodes in the dalteparin group compared to 0 in the apixaban group. 
Moreover, the rates of clinically relevant non-major bleeding were not  significantly higher 
with apixaban versus dalteparin (9% and 6%). The incidence of death was similar in both 
groups — 23.4% in the apixaban versus 26.4% in the dalteparin arm. Most deaths were related 
to cancer — 85.2% and 88.2%, respectively. 
The key finding of this study was that oral apixaban is non-inferior to subcutaneous 
dalteparin for the treatment of VTE in cancer patients since diagnosis up to 6 months. Not 
similar to previous studies involving other DOACs, the occurrence of major bleedings, either 
general or gastrointestinal, were similar in apixaban and dalteparin groups. The clinical 
benefit of treatment prolonged for more than half-year should be assessed in additional 
studies. 
 Cancer patients need to have the possibility to use a convenient and safe drug. The 
treatment regimen for VTE with apixaban and rivaroxaban allows for the administration of 
oral medications from the first day of therapy, what is exceptionally convenient in cases of 
DVT and low-risk incidental PE. However, it also requires a physician to make the right 
decision regarding the choice of DOAC or LMWH based on the type of cancer, 
comorbidities, bleeding risk, concomitant chemotherapy and patient preference. As   a 
satisfactory safety profile of apixaban showed in the CARAVAGGIO trial, it makes that 
selection easier. However, the work is not yet completed. More extensive research is still 
needed to allow this heterogeneous group of patients to be treated in a more individualized 
way allowing all therapies to be more effective and safer. 
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